• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs.苏丹内脏利什曼病的经济负担:对提供者和家庭成本的评估。
Am J Trop Med Hyg. 2013 Dec;89(6):1146-1153. doi: 10.4269/ajtmh.12-0585. Epub 2013 Nov 4.
2
The household costs of visceral leishmaniasis care in south-eastern Nepal.尼泊尔东南部内脏利什曼病护理的家庭费用。
PLoS Negl Trop Dis. 2013;7(2):e2062. doi: 10.1371/journal.pntd.0002062. Epub 2013 Feb 28.
3
The economic burden of visceral leishmaniasis for households in Nepal.尼泊尔家庭内脏利什曼病的经济负担。
Trans R Soc Trop Med Hyg. 2006 Sep;100(9):838-41. doi: 10.1016/j.trstmh.2005.09.017. Epub 2006 Jan 10.
4
Cost of Pediatric Visceral Leishmaniasis Care in Morocco.摩洛哥儿童内脏利什曼病的治疗费用
PLoS One. 2016 Jun 3;11(6):e0155482. doi: 10.1371/journal.pone.0155482. eCollection 2016.
5
The economic impact of visceral leishmaniasis on households in Bangladesh.内脏利什曼病对孟加拉国家庭的经济影响。
Trop Med Int Health. 2006 May;11(5):757-64. doi: 10.1111/j.1365-3156.2006.01604.x.
6
Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.印度比哈尔邦穆扎法尔布尔内脏利什曼病患者的管理成本。
Trop Med Int Health. 2006 Nov;11(11):1715-24. doi: 10.1111/j.1365-3156.2006.01732.x.
7
The economic burden of visceral leishmaniasis and barriers to accessing healthcare in Tigray, North Ethiopia: A field based study.埃塞俄比亚提格雷北部内脏利什曼病的经济负担和获得医疗保健的障碍:一项实地研究。
PLoS Negl Trop Dis. 2024 Oct 15;18(10):e0012423. doi: 10.1371/journal.pntd.0012423. eCollection 2024 Oct.
8
Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan.内脏利什曼病高发地区治疗障碍:印度、孟加拉国、尼泊尔、巴西和苏丹。
Drug Dev Ind Pharm. 2010 Nov;36(11):1312-9. doi: 10.3109/03639041003796648.
9
Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan.人道主义救援干预措施的成本效益分析:苏丹的内脏利什曼病治疗
Health Policy Plan. 1999 Mar;14(1):70-6. doi: 10.1093/heapol/14.1.70.
10
Paying for hospital-based care of Kala-azar in Nepal: assessing catastrophic, impoverishment and economic consequences.尼泊尔黑热病住院治疗费用:评估灾难性、致贫性及经济后果
Health Policy Plan. 2009 Mar;24(2):129-39. doi: 10.1093/heapol/czn052. Epub 2009 Jan 30.

引用本文的文献

1
Leishmaniases: Strategies in treatment development.利什曼病:治疗研发策略
Parasite. 2025;32:18. doi: 10.1051/parasite/2025009. Epub 2025 Mar 5.
2
The economic burden of visceral leishmaniasis and barriers to accessing healthcare in Tigray, North Ethiopia: A field based study.埃塞俄比亚提格雷北部内脏利什曼病的经济负担和获得医疗保健的障碍:一项实地研究。
PLoS Negl Trop Dis. 2024 Oct 15;18(10):e0012423. doi: 10.1371/journal.pntd.0012423. eCollection 2024 Oct.
3
Financial hardship among patients suffering from neglected tropical diseases: A systematic review and meta-analysis of global literature.被忽视的热带病患者的经济困难:全球文献的系统评价和荟萃分析。
PLoS Negl Trop Dis. 2024 May 13;18(5):e0012086. doi: 10.1371/journal.pntd.0012086. eCollection 2024 May.
4
Micro and nanotechnologies: The little formulations that could.微米和纳米技术:小制剂的大作为。
Bioeng Transl Med. 2022 Oct 18;8(2):e10421. doi: 10.1002/btm2.10421. eCollection 2023 Mar.
5
Vector-Borne and Zoonotic Diseases in the Eastern Mediterranean Region: A Systematic Review.《东地中海区域的虫媒和动物源传染病:系统评价》。
J Epidemiol Glob Health. 2023 Mar;13(1):105-114. doi: 10.1007/s44197-023-00091-7. Epub 2023 Feb 9.
6
Review of the neglected tropical diseases programme implementation during 2012-2019 in the WHO-Eastern Mediterranean Region.2012-2019 年世卫组织东地中海区域被忽视热带病规划实施情况审查。
PLoS Negl Trop Dis. 2022 Sep 29;16(9):e0010665. doi: 10.1371/journal.pntd.0010665. eCollection 2022 Sep.
7
Prevalence of human leishmaniasis in Sudan: A systematic review and meta-analysis.苏丹人体利什曼病的患病率:一项系统评价和荟萃分析。
World J Methodol. 2022 Jul 20;12(4):305-318. doi: 10.5662/wjm.v12.i4.305.
8
Overcoming roadblocks in the development of vaccines for leishmaniasis.克服利什曼病疫苗研发中的障碍。
Expert Rev Vaccines. 2021 Nov;20(11):1419-1430. doi: 10.1080/14760584.2021.1990043. Epub 2021 Nov 2.
9
Vulnerabilities to and the Socioeconomic and Psychosocial Impacts of the Leishmaniases: A Review.利什曼病的易感性及其社会经济和心理社会影响:综述
Res Rep Trop Med. 2021 Jun 23;12:135-151. doi: 10.2147/RRTM.S278138. eCollection 2021.
10
Leishmaniasis Beyond East Africa.东非以外地区的利什曼病
Front Vet Sci. 2021 Feb 26;8:618766. doi: 10.3389/fvets.2021.618766. eCollection 2021.

本文引用的文献

1
The household costs of visceral leishmaniasis care in south-eastern Nepal.尼泊尔东南部内脏利什曼病护理的家庭费用。
PLoS Negl Trop Dis. 2013;7(2):e2062. doi: 10.1371/journal.pntd.0002062. Epub 2013 Feb 28.
2
Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.葡甲酸钠(SSG)联合巴龙霉素与 SSG 治疗东非内脏利什曼病的随机对照试验。
PLoS Negl Trop Dis. 2012;6(6):e1674. doi: 10.1371/journal.pntd.0001674. Epub 2012 Jun 19.
3
Drug donated for treatment of visceral leishmaniasis.捐赠用于治疗内脏利什曼病的药物。
Lancet Infect Dis. 2012 Feb;12(2):106-7. doi: 10.1016/s1473-3099(12)70024-5.
4
Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.米替福新单药治疗与联合锑酸钠葡萄糖和脂质体两性霉素 B 治疗东非原发性内脏利什曼病的安全性和疗效:一项随机对照试验研究方案。
Trials. 2011 Jun 30;12:166. doi: 10.1186/1745-6215-12-166.
5
Two-tier charging in Maputo Central Hospital: costs, revenues and effects on equity of access to hospital services.马普托中央医院的双层收费:费用、收入以及对医院服务获取公平性的影响。
BMC Health Serv Res. 2011 Jun 2;11:143. doi: 10.1186/1472-6963-11-143.
6
Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia.内脏利什曼病的典型患者是谁?巴西、东非和南亚患者的人口统计学和营养状况特征。
Am J Trop Med Hyg. 2011 Apr;84(4):543-50. doi: 10.4269/ajtmh.2011.10-0321.
7
Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.单剂量脂质体两性霉素 B(AmBisome®)治疗东非内脏利什曼病:一项随机对照试验的研究方案。
Trials. 2011 Mar 6;12:66. doi: 10.1186/1745-6215-12-66.
8
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.东非地区内脏利什曼病对巴龙霉素反应的地理差异:一项多中心、开放标签、随机试验。
PLoS Negl Trop Dis. 2010 Oct 26;4(10):e709. doi: 10.1371/journal.pntd.0000709.
9
The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India.印度比哈尔邦一个流行区内脏利什曼病对农村家庭的经济影响。
Trop Med Int Health. 2010 Jul;15 Suppl 2:42-9. doi: 10.1111/j.1365-3156.2010.02516.x. Epub 2010 May 6.
10
Household cost-of-illness of visceral leishmaniasis in Bihar, India.印度比哈尔邦内脏利什曼病的家庭疾病负担。
Trop Med Int Health. 2010 Jul;15 Suppl 2:50-4. doi: 10.1111/j.1365-3156.2010.02520.x. Epub 2010 May 6.

苏丹内脏利什曼病的经济负担:对提供者和家庭成本的评估。

The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs.

出版信息

Am J Trop Med Hyg. 2013 Dec;89(6):1146-1153. doi: 10.4269/ajtmh.12-0585. Epub 2013 Nov 4.

DOI:10.4269/ajtmh.12-0585
PMID:24189368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3854893/
Abstract

Visceral leishmaniasis (VL) is a neglected parasitic disease that is fatal if left untreated and is endemic in eastern Sudan. We estimated the direct and indirect costs of treatment of VL from the perspective of the provider and the household at three public hospitals in Gedaref State. The median total cost for one VL episode was estimated to be US$450. Despite the free provision of VL drugs at public hospitals, households bore 53% of the total cost of VL with one episode of VL representing 40% of the annual household income. More than 75% of households incurred catastrophic out-of-pocket expenditures. The length of treatment of 30 days led to important costs for both health providers and households. Alternative treatment regimens that reduce the duration of treatment are urgently needed.

摘要

内脏利什曼病(VL)是一种被忽视的寄生虫病,如果不治疗会致命,并且在苏丹东部流行。我们从提供者和家庭的角度在加达里夫州的三家公立医院估算了治疗内脏利什曼病的直接和间接成本。估计一个内脏利什曼病病例的总费用中位数为 450 美元。尽管公立医院免费提供内脏利什曼病药物,但家庭承担了内脏利什曼病总费用的 53%,一个内脏利什曼病病例占家庭年收入的 40%。超过 75%的家庭发生灾难性的自付费用。30 天的治疗时间给卫生提供者和家庭都带来了重要的成本。迫切需要减少治疗时间的替代治疗方案。